Design and computational analysis of a novel Leptulipin-p28 fusion protein as a multitarget anticancer therapy in breast cancer.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Design and computational analysis of a novel Leptulipin-p28 fusion protein as a multitarget anticancer therapy in breast cancer.
- Published In:
- Toxicology research, 13(5), tfae174 (2024)
- Authors:
- Khalid, Sania, Rehman, Hafiz Muhammad, Al-Qassab, Yasamin, Ahmad, Irfan, Fatima, Tehreem, Mubasher, Mian Muhammad, Kalsoom, Maria, Nadeem, Tariq, Bashir, Hamid
- Database ID:
- RPEP-08543
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08543APA
Khalid, Sania; Rehman, Hafiz Muhammad; Al-Qassab, Yasamin; Ahmad, Irfan; Fatima, Tehreem; Mubasher, Mian Muhammad; Kalsoom, Maria; Nadeem, Tariq; Bashir, Hamid. (2024). Design and computational analysis of a novel Leptulipin-p28 fusion protein as a multitarget anticancer therapy in breast cancer.. Toxicology research, 13(5), tfae174. https://doi.org/10.1093/toxres/tfae174
MLA
Khalid, Sania, et al. "Design and computational analysis of a novel Leptulipin-p28 fusion protein as a multitarget anticancer therapy in breast cancer.." Toxicology research, 2024. https://doi.org/10.1093/toxres/tfae174
RethinkPeptides
RethinkPeptides Research Database. "Design and computational analysis of a novel Leptulipin-p28 ..." RPEP-08543. Retrieved from https://rethinkpeptides.com/research/khalid-2024-design-and-computational-analysis
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.